The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Aldeyra Therapeutics, Inc. | COM | 01438T106 | 3,456 | 594,834 | SH | DFND | 1 | 0 | 594,834 | 0 | |
| Arrowhead Pharmaceuticals, Inc. | COM | 04280A100 | 206,837 | 3,260,869 | SH | DFND | 1 | 0 | 3,260,869 | 0 | |
| BiomX Inc. | COM | 09090D103 | 20,662 | 2,133,402 | SH | DFND | 1 | 0 | 2,133,402 | 0 | |
| Castlight Health, Inc. | CL B | 14862Q100 | 1,079 | 811,295 | SH | DFND | 1 | 0 | 811,295 | 0 | |
| Catalyst Biosciences, Inc. | COM NEW | 14888D208 | 456 | 66,951 | SH | DFND | 1 | 0 | 66,951 | 0 | |
| Genocea Biosciences, Inc. | COM NEW | 372427401 | 298 | 143,964 | SH | DFND | 1 | 0 | 143,964 | 0 | |
| PhaseBio Pharmaceuticals, Inc. | COM | 717224109 | 9,819 | 1,607,044 | SH | DFND | 1 | 0 | 1,607,044 | 0 | |
| Protagonist Therapeutics, Inc. | COM | 74366E102 | 17,267 | 2,449,183 | SH | DFND | 1 | 0 | 2,449,183 | 0 | |
| Provention Bio, Inc. | COM | 74374N102 | 16,762 | 1,124,973 | SH | DFND | 1 | 0 | 1,124,973 | 0 | |
| Senseonics Holdings, Inc | COM | 81727U105 | 481 | 525,632 | SH | DFND | 1 | 0 | 525,632 | 0 | |
| Tracon Pharmaceuticals, Inc. | COM NEW | 89237H209 | 197 | 84,003 | SH | DFND | 1 | 0 | 84,003 | 0 | |